FDA Sets New Rules for Reporting Adverse Trial Events

WASHINGTON -- The FDA has finalized new procedures aimed at speeding up reporting and analysis of potential safety problems encountered in clinical trials while cutting down on adverse-event filings the agency considers useless. Under a final rule... full story

Source: medpagetoday